论文部分内容阅读
目的:观察雷莫司琼在介入术前给药预防由顺铂、表阿霉素等引起的胃肠反应的疗效及其不良反应。方法:恶性肿瘤患者156例,随机分成两组:雷莫司琼和格拉司琼组各78例。入选病例为具备介入动脉化疗或(和)栓塞治疗适应证且化疗方案中均含有顺铂≥50mg/m~2或(和)阿霉素≥40mg/m~2(吡喃阿霉素≥40mg/m~2,表阿霉素≥80mg/m~2)化疗药物。两组分别于化疗前15～30min取雷莫司琼注射液0.3mg,格拉司琼3mg加入地塞米松10mg静脉推注。观察患者第1～3天食欲不振、恶心、呕吐等情况,并观察两种止吐药物的不良反应。结果:化疗后0～6h,0～12h,0～18h和0～24h,第2,3天雷莫司琼和格拉司琼对食欲不振、恶心和止吐作用的有效率相似,差异无显著性(P>0.05)。出现头痛、头重感、口干、便秘、腹泻、身体发热感、疲倦、嗜睡、失眠、焦躁不安等不良反应,其发生率两组比较未见显著性差异。结论:雷莫司琼作为新一代的高效高选择性5-HT_3受体拮抗剂,可以有效的拮抗化疗药物所引起的恶心、呕吐等反应,具有较好的使用安全性,可以广泛应用于临床。
OBJECTIVE: To observe the efficacy and adverse reactions of ramosetron in the prevention of gastrointestinal reactions caused by cisplatin and epirubicin before intervention. Methods: A total of 156 patients with malignant tumor were randomly divided into two groups: ramosetron and granisetron in 78 cases. Selected cases with interventional arterial chemotherapy or (and) embolization indications and chemotherapy regimens containing cisplatin ≥50mg / m ~ 2 or (and) doxorubicin ≥40mg / m ~ 2 (pylopyradomycin ≥40mg / m ~ 2, epirubicin ≥ 80mg / m ~ 2) chemotherapy drugs. Two groups were treated with ramosetron 0.3mg and granisetron 3mg intravenously 10mg dexamethasone 15 ~ 30min before chemotherapy respectively. Patients were observed on day 1 to 3, loss of appetite, nausea, vomiting and other conditions, and observed two antiemetic drugs adverse reactions. Results: The effective rates of ramosetron and granisetron on anorexia, nausea and antiemetic were similar at 0 ~ 6h, 0 ~ 12h, 0 ~ 18h and 0 ~ 24h after chemotherapy (P> 0.05). Headache, headache, dry mouth, constipation, diarrhea, fever, fatigue, lethargy, insomnia, restlessness and other adverse reactions, the incidence of no significant difference between the two groups. Conclusion: Ramosetron, as a new generation of highly selective and selective 5-HT_3 receptor antagonist, can effectively antagonize the response of chemotherapy drugs to nausea and vomiting, has good safety and can be widely used in clinical .